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Triazavirin (TZV) (1) is used to treat diseases caused by 
various types of influenza A and B viruses, including the 
pandemic H5N1 (avian influenza virus).1–6 Research to 
expand the spectrum of action of this drug is ongoing. The 
data obtained make it possible to classify TZV as a first-
line drug in the treatment of tick-borne viral encephalitis.7 
In addition, TZV (1) is undergoing clinical trials as an 
antiviral agent against the pandemic strain of coronavirus 
COVID-19.8–10 
To evaluate the new data obtained on the activity of 
TZV, more complete information on the mechanism of its 
action, bioavailability, and biological transformation would 
be required. To solve these problems, it is advisable to use 
compounds enriched in stable isotopes (2H, 13C, and 15N) 
which can be used as internal standards for chromato-mass 
spectrometry.11,12 This strategy makes it possible to 
investigate blood, serum, and other biological fluids for the 
presence of the studied biologically active compounds and 
their metabolites. The ability to analyze the concentrations 
of a compound and its metabolites is necessary for 
pharmacokinetic studies and in the selection of effective 
doses of drugs. 
Previously, we proposed the synthesis of labeled TZV 
(2H3,
15N3)-1 containing 
2H and 15N atoms in its structure 
(Scheme 1, labeled atoms are indicated in bold). The 
incorporation of stable isotopes was based on the reaction 
of the diazonium salt (2H,15N2)-2 with ethyl nitroacetate 
(15N)-3.13 It is important to note that this compound was 
used as an internal standard in studying the effect of TZV 
(1) on the aggregation of natural peptides prone to self-
association, as exemplified by the β-amyloid peptide (βAP) 
fragment accumulating in the brains of patients with 
Alzheimer's disease, and the cytolytic peptide of bee 
venom melittin.14 
This work presents the preparation of labeled TZV 
(2H3,
13C2,
15N3)-1 containing two additional 
13C atoms 
(Scheme 2). In this case, the inclusion of 13C isotopes in the 
structures of biologically active compounds makes it possible 
to additionally involve the method of 13C NMR spectroscopy 
for the study of metabolic and pharmacokinetic pathways.15,16 
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Enriched potassium thiocyanate and (2H3,
13C)-MeI were 
used as donors of 13C atoms. Treatment of aminoguanidine 
carbonate (15N)-4 (15N, 98%) with labeled KSCN (13C, 95–
98%) gave 5-amino-3-mercaptotriazole (13С,15N)-5 in 60% 
yield (Scheme 2). The presence of 13C and 15N atoms in the 
structure of (13С,15N)-5 was confirmed by the registration 
of the molecular ion [M+H]+ peak with a monoisotopic 
mass of 119.0233 Da in the high-resolution mass spectrum. 
The reaction of compound (13С,15N)-5 with labeled MeI 
(99.5% 2H, 99% 13C) gave aminotriazole (2H3,
13C2,
15N)-6  
in 61% yield. The incorporation of additional 2H and 13C 
labels in this case was proved by mass spectrometry 
([M+H]+ m/z 137.0612). The reaction of aminotriazole 
(2H3,
13C2,
15N)-6 with 15N-nitrous acid generated from 
enriched NaNO2 (98%, 
15N) resulted in the formation of 
diazonium salt (2H3,
13C2,
15N2)-2. Subsequent treatment 
with ethyl nitroacetate (15N)-3 (15N, 98%) afforded 
isotopically enriched triazolotriazine sodium salt dihydrate 
(2H3,
13C2,
15N3)-1 in 43% yield. 
Studying compound (2H3,
13C2,
15N3)-1 by NMR spectro-
scopy it was found that in the 13C NMR spectrum the 
signals of all carbon atoms have additional splitting 
characterized by the constants of the spin-spin interaction 
13С–15N (JC–N) with labeled 
15N atoms. The quantitative 
measurement of JC–N was carried out on the basis of a set of 
one-dimensional 13C NMR experiments recorded with 
selective decoupling from 2H and 15N atoms (Figs. S3–S5, 
Supplementary information file). The values of the 
measured 13С–15N coupling constants are presented in 
Table 1. The presence of spin-spin interactions between the 
13С-2 and 13С-2' atoms with the 15N-1 atom was 
additionally confirmed by the data of the 13С–15N HMBC 
two-dimensional spectrum in which the corresponding 
cross peaks are present (Fig. 1). Analysis of the 13С–15N 
HMBC two-dimensional spectrum also showed the 
presence of a long-range constant (4JC–N) which is due to 
the interaction between 13С-2 and 15N-5 atoms. In addition, 
a set of cross peaks with the corresponding JC–N constants 
between the C-3a, C-6, and C-7 atoms with a natural 
content of the 13C isotope and 15N-enriched N-1, N-5, and 
N-6' atoms was observed in the 13С–15N HMBC spectrum. 
Analysis of the 13С–15N HMBC spectrum also indicated 
the possible signal frequencies of the N-3, N-4, and N-8 
atoms with the natural abundance of the 15N isotope (Fig. 1, 
Table 1). Using the one-dimensional 13C NMR spectrum 
acquired with decoupling from 2H and 15N atoms, the 
geminal coupling constant 13С–13С (2JC–С) between the 
labeled 13С-2 and 13С-2' atoms was recorded (Table 1). At 
the same time, the recording of the one-dimensional 
13C NMR spectrum with decoupling only from 15N atoms 
made it possible to estimate the 2H–13C (1JC–D) 
heteronuclear interaction. The presence of the 1JC–D 
constant in the signal of the C-2' atom (Table 1) 
unambiguously proves the presence of deuterium atoms in 
Scheme 1 
Scheme 2 
13C NMR spectrum 
(175 MHz, DMSO-d6) 
15N NMR spectrum 
(71 MHz, DMSO-d6) 
Atom δ, ppm (J, Hz)* Atom δ, ppm, J, Hz 
C-2 166.4 dddd 
3JС2–D  < 1*** 
2JC2–C2' = 1.2** 
1JС2–N1 = 4.7 (×) 
4JС2–N5 ~ 0.4 (×) 
N-1 259.1 dd 
3JN1–C2' = 2.6 
1JN1–C2 = 4.7 
C-2' 13.3 sept dd 
1JС2'–D = 21.6 
2JC2'–C2 = 1.2** 







C-3a 160.7 dd 
2JС3a–N5 = 2.1 (×)
 
2JС3a–N1 = 0.4 
N-5 397.0 d 
2JN5–N6' = 6.3 
C-6 145.1 ddd 
1JС6–N5 = 1.8 (×)
 
1JС6–N6' 23.4 (×) 
3JС6–N1 1.6 (×) 
N-6' 367.9 d 
2JN5-N6' = 6.3 
C-7 143.5 dddd 
3JC7–C2 = 7.0 
2JС7–N5 = 1.3 
2JС7–N6' = 5.3 (×) 
2JС7–N1 = 3.6 (×) 
N-8*4 226.0 s 
Table 1. Chemical shifts and SSCC of signals 
in the 13С and 15N NMR spectra of compound (2H3,
13C2,
15N3)-1 
* The sign (×) denotes the coupling constants which lead to the 
appearance of cross peaks in the 13C–15N HMBC spectrum (Fig. 1). 
** 13С–13С SSCC were measured with simultaneous decoupling from 
2H-2' and 15N-1 nuclei. 
*** SSCC was not observed due to the large half-width of the 
corresponding 13C signal. Previously, the value of 3JС2–D was estimated at 
0.7 Hz.13 
*4 The signals of atoms with a natural abundance of the 15N isotope were 
detected in the 13C–15N HMBC spectrum.  
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the structure of (2H3,
13C2,
15N3)-1. The signal of the 2'-
13C2H3 
group was observed as a doublet in the one-dimensional 
2H NMR spectrum at ~2.65 ppm (Fig. S1, Supplementary 
information file). The upfield component of the doublet 
was partially overlapped by the signal from the solvent 
DMSO-d6. 
The one-dimensional 15N NMR spectrum of compound 
(2H3,
13C2,
15N3)-1 showed three signals of labeled 
15N 
nitrogen atoms (Table 1, Fig. 1) presented as a doublet of 
doublets at 259.1 ppm (N-1) and two doublets at 397.0 and 
367.9 ppm (N-5 and N-6', respectively). The assignment of 
signals in the one-dimensional 15N NMR spectrum was 
carried out on the basis of measuring the 13С–15N coupling 
constant and analysis of chemical shifts.13 The 15N–15N 
spin-spin interaction is reflected in the structure of the 
signals of the N-5 and N-6' atoms. The multiplicity of the 
resonance signal of the 15N-1 atom is explained by the 
presence of two 13C–15N coupling constants with labeled 
carbon atoms. This conclusion was confirmed by acquiring 
one-dimensional 15N NMR spectra recorded with selective 
decoupling from the 13C-2 and 13C-2' atoms (Fig. S2, 
Supplementary information file). These experiments made 
it possible to quantitatively measure the direct constant 1JC2–N1 
(Table 1). 
To conclude, we have developed methods that allow, in 
addition to the 2H and 15N atoms, to selectively incorporate 
13C isotopes into the structure of the antiviral drug 
Triazavirin. As a result, a sample was obtained containing 
three types of stable isotopes at once which was 
characterized by NMR spectroscopy. The practical use of 
labeled Triazavirin can significantly expand the 
possibilities in a comprehensive study of the bioavailabi-
lity, pharmacokinetics, and metabolic pathways of this 
antiviral drug using mass spectrometry and NMR spectro-
scopy. This, in turn, can contribute to a more rational choice 
of treatment strategies. 
Experimental 
1Н, 13C, and 15N NMR (700, 175, and 71 MHz, 
respectively) and 13C–15N HMBC spectra of compound 
(2H3,
13C2,
15N3)-1 were acquired on a Bruker Avance 700 
spectrometer equipped with a triple resonance sensor (1H, 
13C, 15N) in DMSO-d6, using residual solvent signals 
(2.50 ppm for 1Н nuclei) or solvent signals (40.11 ppm for 
13С nuclei) as internal standard; liquid NН3 (for 
15N nuclei) 
was used as external standard. For measuring 13С–13С and 
13С–15N SSCCs, a previously developed method17 of 
nonlinear approximation of line shapes in one-dimensional 
13C NMR spectra recorded with and without decoupling 
from 2H and 15N nuclei was used. For selective decoupling 
of 15N nuclei, adiabatic pulses (WURST-20) with a length 
of 10–20 ms and an inversion range of ~ 1 kHz (14 ppm) 
for 15N nuclei were used. The decoupling of the 2H nuclei 
was carried out by the WALTZ-16 wideband sequence. 
The 13C–15N HMBC two-dimensional spectra were 
recorded using delays for the transfer of magnetization 
between the 13C and 15N nuclei in the range of 50–100 ms. 
In some cases, selective decoupling of the 15N-1 nucleus  
was achieved using saturation of the corresponding 15N  
frequency during magnetization transfer and 13C detection. 
1Н, 13C, and 15N NMR spectra for compounds (13C,15N)-5 
and (2H3,
13C,15N)-6 were registered on a Bruker Avance II 
spectrometer (400, 100, and 41 MHz, respectively), 
DMSO-d6 solvent. TMS was used as internal standard (for 
13С, 1Н nuclei), liquid ammonia was used as the external 
standard (for 15N nuclei). High-resolution mass spectra 
were recorded on a Finnigan LTQ FT mass spectrometer 
equipped with a 7 Tesla superconducting magnet and an 
Ion Max electrospray ionizer. Melting points were determined 
in open capillaries on a Stuart SMP3 apparatus. 
Ethyl nitroacetate (15N)-313 (15N enrichment 98%) and 
aminoguanidine (15N)-418 (15N enrichment 98%) were 
synthesized according to the previously described methods. 
Labeled MeI (2H, 99.5% and 13С, 99%) was supplied by 
Aldrich. Enriched with stable isotopes sodium nitrate (15N, 
98%) and potassium thiocyanate (13С, 95–98%) were 
supplied by Cambridge Isotope Laboratories. 
5-Amino-3-mercapto-1,2,4-(3-13C,2-15N)triazole ((13C,15N)-5). 
(15N)-Aminoguanidine carbonate (15N)-4 (0.56 g, 4.00 mmol) 
KS13CN (13C, 95–98%; 0.40 g, 4.00 mmol), NH4Cl (0.05 g, 
0.80 mmol), and water (0.18 ml) were mixed together. The 
mixture was heated and stirred at 90°С for 2 h, then 
concentrated HCl (2.70 mmol, 0.46 ml) was added 
dropwise over 2 h and heating was continued at 100°С for 
1 h. Then, a solution of KOH (0.25 g, 4.40 mmol) in H2O 
(0.25 ml) was added to the reaction mixture. The mixture 
was heated at 100°С for 2 h, cooled, filtered, and the 
filtrate was acidified with concentrated HCl to pH 2. The 
formed precipitate was filtered off and washed with H2O. 
The resulting labeled product (13C,15N)-5 (0.283 g, 60%, 
13C 95–98%, 15N 98%) was used in further syntheses without 
purification. 1H NMR spectrum, δ, ppm (J, Hz): 5.74 (2H, 
Figure 1. Fragments of the 13C–15N HMBC spectrum of com-
pound (2H3,
13C2,
15N3)-1 and the corresponding segments of the 
one-dimensional 13C and 15N NMR spectra. The intensity of the 
fragments of the one-dimensional 13C NMR spectrum shown in 
the panels on the right is increased relative to the fragment on the 
left panel. The 13C–15N HMBC spectrum showing correlations 
of  15N nuclei with 13C-2 nucleus was obtained with selective de-
coupling from 15N-1 nucleus (the signal area is denoted by a dot-
ted circle). 
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br. s, NH2); 12.06 (1H, br. s, NH); 12.25 (1H, dd, 
1JH–N = 107.6, 
2JH–C = 10.0, NH). 
13C NMR spectrum, 
δ, ppm (J, Hz): 152.5 (CNH2, 
2JC–C = 5.5); 162.8 (CS,  
1JC–N = 12.5). 
15N NMR spectrum, δ, ppm (J, Hz): 192.2 
(1JС–N = 12.5). Found, m/z: 119.0233 [M+H]
+. C13СH5N3
15NS. 





triazole (13C,15N)-5 (0.118 g, 1.00 mmol) was added to a 
solution of KOH (0.062 g, 1.10 mmol) in H2O (2.00 ml). The 
solution was then cooled to 0°С, 13C2H3I (
2H 99.5%, 13C 
99%; 0.160 g, 1.10 mmol) was added, and the mixture was 
stirred for 6 h. After evaporation of H2O under reduced 
pressure at a temperature not exceeding 60°C to about half 
of the initial volume, the formed precipitate was filtered 
off, washed with ice-cold H2O, and dried. The obtained 
5-amino-3-methylmercapto-1,2,4-triazole (2H3,
13C,15N)-6 
(0.082 g, 61%, 2H 99.5%, 13C 99%, 15N 98%) was used in 
further syntheses without purification. 1H NMR spectrum, 
δ, ppm: 5.94 (2H, br. s, NH2); 11.88 (1H, br. s, NH). 
13C NMR spectrum, δ, ppm (J, Hz): 13.0 (sept, 1JC–D = 21.4, 
C2H3); 156.3 (CS); 157.9 (CNH2). The SSCC for 
13С–15N 
was not observed due to signal broadening. 15N NMR 
spectrum, δ, ppm: 261.4. Found, m/z: 137.0612 [M+H]+. 
C13С2H4
2H3N3
15NS. Calculated, m/z: 137.0612. 
2-(2H3)Methylsulfanyl-6-(
15N)nitro(2-13C,1,5-15N2)[1,2,4]-
triazolo[5,1-с][1,2,4]triazin-7(4H)-one sodium salt 
dihydrate ((2H3,
13С2,
15N3)-1). Labeled 5-amino-3-methyl- 
mercapto-1,2,4-triazole (2H3,
13С2,
15N)-6 (0.2 g, 1.47 mmol) 
was added to a mixture of H2O (2.00 ml) and concentrated 
HCl (0.25 ml). The resulting mixture was cooled to ‒5°С, 
and a solution of Na15NO2 (0.111 g, 1.50 mmol) in H2O 
(1.00 ml) was added dropwise. The reaction mixture was 
stirred for 10 min and added to a cooled (0°С) solution of 
ethyl 15N-nitroacetate ((15N)-3) (0.30 ml) in 17% aqueous 
Na2CO3 (4.00 ml). The reaction mixture was stirred for 2 h 
at room temperature, the formed precipitate was filtered 
and recrystallized from 50% AcOH. Yield 0.185 g (43%, 
2H 99%, 13C 99%, 15N 98%), yellow crystals, mp >300°C. 








15N3O3SNa·2H2O. Calculated, %: 
C 21.09; H 3.42; N 29.58.  
 
Supplementary information file containing 2H, 13C, and 
15N NMR spectra of compound (2H3,
13С2,
15N3)-1 is 
available at the journal website at http://link.springer.com/
journal/10593. 
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